Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 403 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, intranasal Clear all
Terminated Phase 3 Interventional Results available

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

NCT05011396
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Garden Grove, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

FLU-VACS Comparative Study in Adults

NCT00133523
View directory record Official record
Conditions
Influenza
Interventions
Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
2,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
6
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 6, 2026, 4:10 PM EDT
Recruiting Phase 1 Interventional

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

NCT03860233
View directory record Official record
Conditions
Sleep Apnea, Sleep Apnea, Obstructive
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Vivek Jain
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 6, 2026, 4:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Cannabis and Opioid Use Disorder

NCT05729932
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Inhaled vaporized cannabis, Intransal opioid
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Safety of a New Influenza Vaccine

NCT01104493
View directory record Official record
Conditions
Healthy
Interventions
Monovalent Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

NCT04292535
View directory record Official record
Conditions
Insulin, Exercise
Interventions
Placebo into the intranasal mucosa, 20 IU NovoLog Insulin aspart into the intranasal mucosa, 40 IU NovoLog Insulin aspart into the intranasal mucosa, 60 IU NovoLog Insulin aspart into the intranasal mucosa, 80 IU NovoLog Insulin aspart into the intranasal mucosa, 100 IU NovoLog Insulin aspart into the intranasal mucosa, 120 IU NovoLog Insulin aspart into the intranasal mucosa
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of DEX-IN During Outpatient Procedures

NCT03348423
View directory record Official record
Conditions
Pain
Interventions
DEX-IN, Fentanyl, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 1 Interventional

Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers

NCT01989533
View directory record Official record
Conditions
Vaccine Response
Interventions
Ad4-mgag, Ad4-EnvC150, gp 120 Protein Boost
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Anaheim, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

NCT03158038
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Monovalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional

Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia

NCT01217788
View directory record Official record
Conditions
Social Phobia, Social Anxiety Disorder
Interventions
PH94B intranasal spray
Drug
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06691113
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 3 Interventional

Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure

NCT00665977
View directory record Official record
Conditions
Obstructive Sleep Apnea, Nasal Congestion, Sinus Congestion
Interventions
Thermosmart & placebo, Placebo Device & Nasacort, Placebo Arm
Drug · Device
Lead sponsor
Clayton Sleep Insititute
Industry
Eligibility
16 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 1 Interventional Results available

Safety Study to Evaluate FluMist in Immunocompromised Children

NCT00112112
View directory record Official record
Conditions
Cancer
Interventions
FluMist, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Rochester, New York • Stony Brook, New York • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

NCT02682225
View directory record Official record
Conditions
Drug Abuse
Interventions
Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 6, 2026, 4:10 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Post Operative Delirium Study

NCT04635774
View directory record Official record
Conditions
Delirium
Interventions
Insulin, Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 6, 2026, 4:10 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

NCT00951743
View directory record Official record
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423
View directory record Official record
Conditions
Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions
B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Months to 59 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Midazolam in Children as a Pre-Operative Sedative

NCT02314546
View directory record Official record
Conditions
Sedation, Conscious
Interventions
Midazolam, xylocaine, saline placebo
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Months to 7 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Results available

Naloxone, Hypoglycemia and Exercise

NCT03149770
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Naloxone then placebo, Placebo then Naloxone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers

NCT00748956
View directory record Official record
Conditions
Mood Disorder, Anxiety Disorders
Interventions
Low dose NPY, High dose NPY, Placebo
Drug
Lead sponsor
Dennis Charney
Other
Eligibility
25 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 6, 2026, 4:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder

NCT01856530
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Stefan G. Hofmann
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 6, 2026, 4:10 PM EDT